1. |
|
|
2. |
- Lumbers, R. T., et al.
(author)
-
The genomics of heart failure: design and rationale of the HERMES consortium
- 2021
-
In: Esc Heart Failure. - : Wiley. - 2055-5822. ; 8:6, s. 5531-5541
-
Journal article (peer-reviewed)abstract
- Aims The HERMES (HEart failure Molecular Epidemiology for Therapeutic targets) consortium aims to identify the genomic and molecular basis of heart failure. Methods and results The consortium currently includes 51 studies from 11 countries, including 68 157 heart failure cases and 949 888 controls, with data on heart failure events and prognosis. All studies collected biological samples and performed genome-wide genotyping of common genetic variants. The enrolment of subjects into participating studies ranged from 1948 to the present day, and the median follow-up following heart failure diagnosis ranged from 2 to 116 months. Forty-nine of 51 individual studies enrolled participants of both sexes; in these studies, participants with heart failure were predominantly male (34-90%). The mean age at diagnosis or ascertainment across all studies ranged from 54 to 84 years. Based on the aggregate sample, we estimated 80% power to genetic variant associations with risk of heart failure with an odds ratio of >1.10 for common variants (allele frequency > 0.05) and >1.20 for low-frequency variants (allele frequency 0.01-0.05) at P < 5 x 10(-8) under an additive genetic model. Conclusions HERMES is a global collaboration aiming to (i) identify the genetic determinants of heart failure; (ii) generate insights into the causal pathways leading to heart failure and enable genetic approaches to target prioritization; and (iii) develop genomic tools for disease stratification and risk prediction.
|
|
3. |
- Tardif, Jean-Claude, et al.
(author)
-
Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib.
- 2015
-
In: Circulation. - 1942-325X .- 1942-3268. ; 8:2, s. 372-382
-
Journal article (peer-reviewed)abstract
- BACKGROUND: Dalcetrapib did not improve clinical outcomes, despite increasing high-density lipoprotein cholesterol by 30%. These results differ from other evidence supporting high-density lipoprotein as a therapeutic target. Responses to dalcetrapib may vary according to patients' genetic profile.METHODS AND RESULTS: We conducted a pharmacogenomic evaluation using a genome-wide approach in the dal-OUTCOMES study (discovery cohort, n=5749) and a targeted genotyping panel in the dal-PLAQUE-2 imaging trial (support cohort, n=386). The primary endpoint for the discovery cohort was a composite of cardiovascular events. The change from baseline in carotid intima-media thickness on ultrasonography at 6 and 12 months was evaluated as supporting evidence. A single-nucleotide polymorphism was found to be associated with cardiovascular events in the dalcetrapib arm, identifying the ADCY9 gene on chromosome 16 (rs1967309; P=2.41×10(-8)), with 8 polymorphisms providing P<10(-6) in this gene. Considering patients with genotype AA at rs1967309, there was a 39% reduction in the composite cardiovascular endpoint with dalcetrapib compared with placebo (hazard ratio, 0.61; 95% confidence interval, 0.41-0.92). In patients with genotype GG, there was a 27% increase in events with dalcetrapib versus placebo. Ten single-nucleotide polymorphism in the ADCY9 gene, the majority in linkage disequilibrium with rs1967309, were associated with the effect of dalcetrapib on intima-media thickness (P<0.05). Marker rs2238448 in ADCY9, in linkage disequilibrium with rs1967309 (r(2)=0.8), was associated with both the effects of dalcetrapib on intima-media thickness in dal-PLAQUE-2 (P=0.009) and events in dal-OUTCOMES (P=8.88×10(-8); hazard ratio, 0.67; 95% confidence interval, 0.58-0.78).CONCLUSIONS: The effects of dalcetrapib on atherosclerotic outcomes are determined by correlated polymorphisms in the ADCY9 gene.CLINICAL TRIAL INFORMATION: URL: http://www.clinicaltrials.gov. Unique identifiers: NCT00658515 and NCT01059682.
|
|
4. |
- Herrmann, T. M., et al.
(author)
-
Effects of mining on reindeer/caribou populations and indigenous livelihoods : Community-based monitoring by Sami reindeer herders in Sweden and First Nations in Canada
- 2014
-
In: The Polar Journal. - : Taylor and Francis Ltd.. - 2154-896X .- 2154-8978. ; 4:1, s. 28-51
-
Journal article (peer-reviewed)abstract
- This paper explores the effects of human disturbances associated with mine development in the Arctic on habitat and populations of reindeer/caribou (both Rangifer tarandus), and implications for reindeer husbandry and caribou hunting of indigenous Sami people in Sweden and First Nations in Canada. Through three case studies, we illustrate how Cree and Naskapi communities develop community- based geospatial information tools to collect field data on caribou migration and habitat changes, and how Sami reindeer herders use GIS to gather information about reindeer husbandry to better communicate impacts of mining on reindeer grazing areas. Findings indicate impacts on the use of disturbed habitat by reindeer/caribou, on migration routes, and northern livelihoods. The three cases present novel methods for community-based environmental monitoring, with applications in hazards mapping and denote the active engagement of indigenous communities in polar environmental assessments, generating community-oriented data for land use management decisions. They also illustrate how technology can lead to better communication and its role for empowerment.
|
|